Key Highlights
- SILO shares climbed 47.55% during after-hours session Monday, reaching $0.52
- European Patent Office delivered Rule 71(3) notice indicating planned patent grant for preventative PTSD treatment
- Patent application encompasses therapeutic methods utilizing serotonin 4 (5-HT4) receptor agonists for preventing stress-related fear and depression
- Columbia University exclusively licenses this patent to Silo Pharma, with anticipated protection across key European territories
- Trading at approximately $4.98 million market capitalization, SILO remains significantly below its $1.18 yearly peak
Monday brought positive momentum for Silo Pharma after receiving a Rule 71(3) communication from the European Patent Office (EPO) — a procedural notification signaling the agency’s intention to award patent protection for an innovative PTSD prevention treatment.
Titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” the patent submission centers on the serotonin 4 (5-HT4) receptor mechanism. This therapeutic strategy emphasizes blocking stress-triggered fear responses and depressive tendencies proactively, diverging from conventional post-symptom intervention methods.
Columbia University holds the original rights, granting Silo Pharma exclusive licensing privileges. The biotechnology firm is currently assessing Unitary Patent safeguards and country-specific validations throughout European jurisdictions to maximize territorial reach.
Chief Executive Officer Eric Weisblum characterized the development as a “high-value milestone” that bolsters the organization’s worldwide intellectual property framework.
Patent Scope and Claims
The approved claims encompass preventative methodologies for stress-triggered fear responses, depression-like symptoms, and associated mood disorders through specific 5-HT4 receptor agonist compounds.
This represents a departure from conventional PTSD therapies that address manifestations post-development. Silo’s methodology concentrates on establishing psychological resilience before stressful exposures occur.
The intellectual property directly underpins SPC-15, Silo’s flagship PTSD development program. Additional pipeline candidates include SP-26 targeting fibromyalgia and chronic pain conditions, alongside early-stage programs investigating Alzheimer’s disease interventions.
Market Performance Analysis
SILO concluded Monday’s standard trading session at $0.36 before surging to $0.52 during extended-hours activity — representing a 47.55% advance.
The twelve-month trading range illustrates substantial volatility: shares touched $1.18 at their zenith and bottomed at $0.22. This dramatic fluctuation characterizes a microcap enterprise valued near $5 million.
Benzinga’s equity evaluation system indicated SILO exhibited unfavorable price momentum across multiple timeframes preceding Monday’s announcement.
The after-market surge propelled shares above the $0.50 threshold for the first time in recent sessions, although pricing remains considerably beneath the annual high-water mark.
Following formal EPO issuance, the patent is projected to secure Silo’s preventative PTSD therapy throughout principal European commercial markets.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
